Latest Market News
• Bank of America broke key resistance level 34.00 • Likely to rise to resistance level 36.00 Bank of America recently broke the key resistance level 34.00 (which has been continually reversing the price from the middle of July). The breakout of the resistance level 34.00 continues the active C-wave of the ABC correction (B). […]
• USDJPY reversed from support level 131.40 • Likely to rise to resistance level 136.00 USDJPY recently reversed up from the support level 131.40 (former monthly high from May), intersecting with the lower daily Bollinger Band and the 61.8% Fibonacci correction of the upward impulse wave 1 from May. The upward reversal from the support […]
What comes to mind when you think of Gucci? Designer handbags, fashion jewelry, elegant Swiss watches? What about payment integration with an ERC-20 governance and utility token that wants to power Web3? Rolls off the tongue, doesn’t it? The iconic Italian fashion brand announced this week it would expand its payment options to include the […]
Stocks ended mostly lower Friday but off session lows as investors assessed how the Federal Reserve will respond to data that showed the U.S. economy added 528,000 jobs in July, far exceeding the 258,000 expected by economists. Fed-funds futures traders penciled in a nearly 70% probability of a 75 basis point rate hike when policy […]
Bitcoin (BTC) saw fresh rejection at $23,500 resistance on Aug. 5 as United States equities failed to embrace surprisingly strong payroll data. BTC/USD 1-hour candle chart (Bitstamp). Source: TradingView “Collapsing real wages” poke fun at payroll print Data from Cointelegraph Markets Pro and TradingView followed BTC/USD as bears kept the market in its intraday trading […]
Shares of Global Blood Therapeutics Inc. GBT, +36.89% jumped 9.5% in trading on Friday after The Wall Street Journal reported that Pfizer Inc. PFE, -1.34% is considering buying the company for about $5 billion. There were media reports earlier this week that Global Blood Therapeutics, which markets a sickle-cell treatment, is attracting takeover interest. The […]